BBC vs IBBQ: Grades, Fees and Holdings Compared

Virtus Biotech Clinical Trials ETF

BBCDNYSE Arca

Invesco Nasdaq Biotechnology ETF

IBBQANasdaq

Overlap

14.0%by weight

Expense ratio

IBBQ −0.46pt a year

BBC0.65%IBBQ0.19%

Avg volume · 30D

IBBQ 1.5×the volume

BBC24.7KIBBQ36.6K

5Y return · a year

IBBQ +8.7pt

BBC0.0%IBBQ+8.7%

BBC vs IBBQ Performance

Oct 29, 2021 – Oct 30, 2026

0.0%BBC+51.6%IBBQ

Expense ratio: BBC 0.65%; IBBQ 0.19%, better
Fund size: BBC $35M; IBBQ $120M
1Y total return: BBC +35.6%; IBBQ +37.1%, better
Yield (12M): BBC 1.52%, better; IBBQ 1.08%
Holdings: BBC 130; IBBQ 250
Avg volume (30D): BBC 24.7K sh; IBBQ 36.6K sh, better
NAV per share: BBC $44.05; IBBQ $36.17
52W range

ETF.net Grade

Pillar letters and Scores for BBC, IBBQ, with each pillar’s weight
Pillar	BBC	IBBQ
Cost30% weight	F13	A100Higher
Mission25% weight	C45	A84Higher
Risk15% weight	F12	A73Higher
Tradability15% weight	F22	C48Higher
Holdings10% weight	A93Higher	B62
Durability5% weight	C48Higher	C42

Rank among Biotech & Genomics funds

How we build Categories ›

Same Category. BBC and IBBQ are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds

See all 17 ›

IBBQ ranks 2nd and BBC 16th of 17 funds in the Biotech & Genomics Category.

Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
Rank 3AIBBiShares Biotechnology ETFScore 75
Rank 15DARKGARK Genomic Revolution ETFScore 33
Rank 16DBBCVirtus Biotech Clinical Trials ETFScore 31
Rank 17DCANCTema Oncology ETFScore 30

Our read on each fund

ETF.net Research

BBCDVirtus Biotech Clinical Trials ETF

IBBQAInvesco Nasdaq Biotechnology ETF

In short

BBC Most biotech funds blend approved-drug cash machines with science projects. BBC keeps only the science projects: US-listed biotechs whose lead drug is still in clinical trials, spread across roughly 200 names.

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

Stated mandate

BBC The Fund seeks to track, before fees and expenses, the investment results of the LifeSci Biotechnology Clinical Trials Index. The Index comprises U.S.-listed biotechnology stocks with a lead drug in clinical-stage development.

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

Why people hold it

BBC A genuinely narrow mandate: the index takes U.S.-listed biotechs with a lead drug in clinical-stage development, so commercial-stage giants stay out.
Roughly 200 holdings, so one failed readout is a dent, not the whole fund.
The basket lines up tightly with what the prospectus says it owns, one of the cleaner mandate-to-portfolio matches in biotech.
Running since 2014, which makes it one of the longer-lived pure clinical-stage plays rather than a recent theme launch.

IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

Worth knowing

BBC At 0.65% a year it costs more than the typical biotech fund, and more than broad peers like XBI (0.35%) and IBB (0.44%).
Small asset base and thin trading, so spreads can widen and large orders move the price.
Pre-approval biotech is binary by nature, and on our review the fund sits in the lower tier of its biotech peer group overall.

IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

Full BBC profile⁠

Full IBBQ profile⁠

BBC vs IBBQ Holdings

How BBC and IBBQ differ

Overlap by weight

14.0%

Shared holdings make up 71.2% of BBC and 15.6% of IBBQ.

Level by level

Holdings88 in both14.0%
Countryby domicile93.4%
Asset classEquity100%
Sector2 Sectors100%

Sector

Sector weights in BBC and IBBQ, widest gap first
Sector	More in BBCMore in IBBQ	BBC	IBBQ
Health Care	Same weight	100.0%	100.0%
Financials	Same weight	0.0%	0.0%

Country, concentration and asset class

Country by domicile

Country weights in BBC and IBBQ, widest gap first
Country	More in BBCMore in IBBQ	BBC	IBBQ
United States	IBBQ +5.2 points	90.0%	95.2%
Canada	BBC +1.9 points	2.4%	0.5%
Netherlands	BBC +1.6 points	2.0%	0.4%
Ireland	BBC +1.5 points	1.6%	0.1%
France	IBBQ +0.9 points	0.0%	0.9%
Switzerland	BBC +0.7 points	1.1%	0.4%
China	BBC +0.5 points	0.6%	0.1%
Other countries (6)	IBBQ +0.2 points	2.3%	2.5%

Concentration

Weight in the 10 largest Holdings

BBC16.0%
IBBQ47.2%

Securities held

BBC129
IBBQ248

Asset class

BBC: Equity
IBBQ: Equity

Holdings

Only in BBC41
In both88
Only in IBBQ160

Only in BBC

41 securities, 28.8% of BBC by weight

SpyGlass Pharma Inc1.34%
Viridian Therapeutics Inc1.15%
VeraDermics Inc1.14%
Biohaven Ltd1.11%
LB Pharmaceuticals Inc1.07%
Palvella Therapeutics Inc1.06%
Achieve Life Sciences Inc0.99%
SELLAS Life Sciences Group Inc0.98%
Generate Biomedicines Inc0.97%
Monopar Therapeutics Inc0.91%
Alto Neuroscience Inc0.83%
Belite Bio Inc0.82%
Damora Therapeutics Inc0.80%
Rezolute Inc0.78%
Dianthus Therapeutics Inc0.76%
Adlai Nortye Group Ltd0.76%
Immunome Inc0.75%
Celldex Therapeutics Inc0.72%
Immix Biopharma Inc0.72%
Viking Therapeutics Inc0.71%
Jade Biosciences Inc0.70%
Assembly Biosciences Inc0.69%
Climb Bio Inc0.68%
ProKidney Corp0.68%
Crescent Biopharma Inc0.60%
Celcuity Inc0.59%
Arcus Biosciences Inc0.59%
Invivyd Inc0.59%
Immatics NV0.59%
Lexicon Pharmaceuticals Inc0.58%
Aktis Oncology Inc0.58%
Oculis Holding AG0.56%
MoonLake Immunotherapeutics0.51%
Nektar Therapeutics0.50%
Relmada Therapeutics Inc0.39%
Avalo Therapeutics Inc0.38%
Compass Therapeutics Inc0.28%
BridgeBio Oncology Therapeutics Inc0.26%
Evommune Inc0.26%
MapLight Therapeutics Inc0.21%
Capricor Therapeutics Inc0.19%

Only in IBBQ

160 securities, 84.4% of IBBQ by weight

Gilead Sciences Inc8.81%
Amgen Inc8.35%
Vertex Pharmaceuticals Inc7.73%
Moderna Inc5.67%
Regeneron Pharmaceuticals Inc5.27%
Illumina Inc2.79%
Biogen Inc2.35%
Royalty Pharma PLC1.87%
Roivant Sciences Ltd1.73%
United Therapeutics Corp1.62%
Guardant Health Inc1.58%
Insmed Inc1.55%
Argenx SE1.55%
Incyte Corp1.51%
Alnylam Pharmaceuticals Inc1.48%
Viatris Inc1.40%
Medpace Holdings Inc1.20%
Exelixis Inc1.04%
Ascendis Pharma A/S0.99%
Halozyme Therapeutics Inc0.95%
Neurocrine Biosciences Inc0.95%
Bridgebio Pharma Inc0.90%
Tempus AI Inc0.87%
Jazz Pharmaceuticals PLC0.86%
BeOne Medicines Ltd0.85%
Twist Bioscience Corp0.73%
BioMarin Pharmaceutical Inc0.71%
BioNTech SE0.66%
Caris Life Sciences Inc0.65%
Madrigal Pharmaceuticals Inc0.63%
10X Genomics Inc0.63%
Krystal Biotech Inc0.61%
Protagonist Therapeutics Inc0.60%
Sanofi SA0.59%
ImmunityBio Inc0.59%
Cytokinetics Inc0.56%
Arrowhead Pharmaceuticals Inc0.55%
Alkermes PLC0.49%
Axsome Therapeutics Inc0.48%
Amneal Pharmaceuticals Inc0.47%
Ionis Pharmaceuticals Inc0.47%
GRAIL Inc0.45%
Ligand Pharmaceuticals Inc0.41%
Rhythm Pharmaceuticals Inc0.41%
Mirum Pharmaceuticals Inc0.36%
Genmab A/S0.35%
PTC Therapeutics Inc0.34%
CRISPR Therapeutics AG0.33%
Abivax SA0.32%
Travere Therapeutics Inc0.30%

Weight gaps

All 88 Holdings in both funds, largest gap first.

Holding weights in BBC and IBBQ, widest gap first
Holding	More in BBCMore in IBBQ	BBC	IBBQ
First Tracks Biotherapeutics IncTRAX	BBC +1.84 points	1.94%	0.10%
Kodiak Sciences IncKOD	BBC +1.84 points	2.24%	0.40%
Revolution Medicines IncRVMD	IBBQ +1.66 points	0.94%	2.60%
Xencor IncXNCR	BBC +1.66 points	1.80%	0.14%
AbCellera Biologics IncABCL	BBC +1.62 points	1.89%	0.27%
Replimune Group IncREPL	BBC +1.38 points	1.48%	0.10%
Prime Medicine IncPRME	BBC +1.37 points	1.43%	0.06%
Amylyx Pharmaceuticals IncAMLX	BBC +1.26 points	1.49%	0.23%
4D Molecular Therapeutics IncFDMT	BBC +1.06 points	1.10%	0.04%
Nurix Therapeutics IncNRIX	BBC +1.03 points	1.21%	0.18%
Vor BioPharma IncVOR	BBC +1.02 points	1.10%	0.08%
MBX Biosciences IncMBX	BBC +0.99 points	1.16%	0.17%
Zenas Biopharma IncZBIO	BBC +0.98 points	1.10%	0.12%
Janux Therapeutics IncJANX	BBC +0.93 points	1.00%	0.07%
Vir Biotechnology IncVIR	BBC +0.90 points	1.03%	0.13%
Maze Therapeutics IncMAZE	BBC +0.90 points	1.01%	0.11%
Recursion Pharmaceuticals IncRXRX	BBC +0.88 points	1.02%	0.14%
Definium Therapeutics IncDFTX	BBC +0.84 points	1.16%	0.32%
Septerna IncSEPN	BBC +0.81 points	0.95%	0.14%
REGENXBIO IncRGNX	BBC +0.81 points	0.84%	0.03%
Cullinan Therapeutics IncCGEM	BBC +0.80 points	0.86%	0.06%
Prothena Corp PLCPRTA	BBC +0.79 points	0.82%	0.03%
ORIC Pharmaceuticals IncORIC	BBC +0.76 points	0.82%	0.06%
Arvinas IncARVN	BBC +0.76 points	0.79%	0.03%
Relay Therapeutics IncRLAY	BBC +0.73 points	1.00%	0.27%
Candel Therapeutics IncCADL	BBC +0.73 points	0.77%	0.04%
Disc Medicine IncIRON	BBC +0.72 points	0.92%	0.20%
Design Therapeutics IncDSGN	BBC +0.72 points	0.76%	0.04%
Sana Biotechnology IncSANA	BBC +0.72 points	0.77%	0.05%
Neurogene IncNGNE	BBC +0.71 points	0.75%	0.04%
Intellia Therapeutics IncNTLA	BBC +0.71 points	0.83%	0.12%
MeiraGTx Holdings plcMGTX	BBC +0.71 points	0.77%	0.06%
Arbutus Biopharma CorpABUS	BBC +0.71 points	0.76%	0.05%
Bicycle Therapeutics PLCBCYC	BBC +0.71 points	0.72%	0.01%
Aura Biosciences IncAURA	BBC +0.70 points	0.74%	0.04%
Rocket Pharmaceuticals IncRCKT	BBC +0.68 points	0.70%	0.02%
Pharvaris NVPHVS	BBC +0.68 points	0.83%	0.15%
GH Research PLCGHRS	BBC +0.68 points	0.77%	0.09%
Compass Pathways PlcCMPS	BBC +0.67 points	0.77%	0.10%
Ideaya Biosciences IncIDYA	BBC +0.66 points	0.86%	0.20%
Savara IncSVRA	BBC +0.64 points	0.71%	0.07%
Oruka Therapeutics IncORKA	BBC +0.64 points	1.05%	0.41%
Solid Biosciences IncSLDB	BBC +0.64 points	0.68%	0.04%
Annexon IncANNX	BBC +0.60 points	0.65%	0.05%
Altimmune IncALT	BBC +0.59 points	0.62%	0.03%
Corvus Pharmaceuticals IncCRVS	BBC +0.59 points	0.65%	0.06%
uniQure NVQURE	BBC +0.59 points	0.70%	0.11%
Edgewise Therapeutics IncEWTX	BBC +0.58 points	0.85%	0.27%
AnaptysBio IncANAB	BBC +0.57 points	0.66%	0.09%
Beam Therapeutics IncBEAM	BBC +0.56 points	0.75%	0.19%
Mineralys Therapeutics IncMLYS	BBC +0.56 points	0.68%	0.12%
Stoke Therapeutics IncSTOK	BBC +0.56 points	0.67%	0.11%
CytomX Therapeutics IncCTMX	BBC +0.55 points	0.58%	0.03%
Inhibrx Biosciences IncINBX	BBC +0.54 points	0.61%	0.07%
Vera Therapeutics IncVERA	BBC +0.54 points	0.68%	0.14%
Enliven Therapeutics IncELVN	BBC +0.53 points	0.74%	0.21%
Olema Pharmaceuticals IncOLMA	BBC +0.52 points	0.56%	0.04%
Tyra Biosciences IncTYRA	BBC +0.52 points	0.60%	0.08%
Lexeo Therapeutics IncLXEO	BBC +0.51 points	0.53%	0.02%
Dyne Therapeutics IncDYN	BBC +0.51 points	0.71%	0.20%
Tectonic Therapeutic IncTECX	BBC +0.49 points	0.51%	0.02%
Erasca IncERAS	BBC +0.48 points	0.81%	0.33%
Taysha Gene Therapies IncTSHA	BBC +0.47 points	0.56%	0.09%
Allogene Therapeutics IncALLO	BBC +0.47 points	0.50%	0.03%
CG oncology IncCGON	BBC +0.45 points	0.81%	0.36%
Kymera Therapeutics IncKYMR	BBC +0.43 points	1.08%	0.65%
Wave Life Sciences IncWVE	BBC +0.42 points	0.47%	0.05%
Scholar Rock Holding CorpSRRK	BBC +0.42 points	0.76%	0.34%
Vaxcyte IncPCVX	BBC +0.41 points	1.00%	0.59%
Rapport Therapeutics IncRAPP	BBC +0.41 points	0.48%	0.07%
Upstream Bio IncUPB	BBC +0.40 points	0.41%	0.01%
Monte Rosa Therapeutics IncGLUE	BBC +0.39 points	0.45%	0.06%
Cabaletta Bio IncCABA	BBC +0.38 points	0.40%	0.02%
Cogent Biosciences IncCOGT	BBC +0.38 points	0.73%	0.35%
Spyre Therapeutics IncSYRE	BBC +0.38 points	0.93%	0.55%
Newamsterdam Pharma Co NVNAMS	BBC +0.36 points	0.52%	0.16%
ArriVent Biopharma IncAVBP	BBC +0.35 points	0.40%	0.05%
Xenon Pharmaceuticals IncXENE	BBC +0.32 points	0.55%	0.23%
Praxis Precision Medicines IncPRAX	BBC +0.31 points	0.82%	0.51%
Tango Therapeutics IncTNGX	BBC +0.31 points	0.55%	0.24%
Bicara Therapeutics IncBCAX	BBC +0.30 points	0.34%	0.04%
Immunovant IncIMVT	BBC +0.28 points	0.67%	0.39%
Structure Therapeutics IncGPCR	BBC +0.28 points	0.39%	0.11%
BioAge Labs IncBIOA	BBC +0.23 points	0.25%	0.02%
Alumis IncALMS	BBC +0.16 points	0.22%	0.06%
Sionna Therapeutics IncSION	BBC +0.07 points	0.08%	0.01%
Summit Therapeutics IncSMMT	BBC +0.06 points	0.88%	0.82%
EyePoint IncEYPT	BBC +0.02 points	0.02%	<0.01%

All 198 BBC holdings⁠All 247 IBBQ holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BBC vs IBBQ Cost

Overpaying BBC vs IBBQ

$8,765

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

BBC 0.65%
$12,717
IBBQ 0.19%
$3,952

Amount$10,000

Years30 years

Cost over time

BBC 0.65%
IBBQ 0.19%
Overpaying

Year by year

Year	BBC	IBBQ	Overpaying
10	$1,163	$347	$816
20	$4,440	$1,351	$3,089
30	$12,717	$3,952	$8,765

Expense ratio

0.65%BBC
0.19%IBBQ, cheaper

IBBQ0.19%BBC0.65%

0.19%0.75%

Middle half of Biotech & Genomics funds
Median 0.47%

IBBQ cheapest of 17 funds

BBC 15th cheapest of 17 funds

BBC vs IBBQ Dividends

Last 12 months to Oct 30, 2026

Yield (12M): BBC 1.52%, better; IBBQ 1.08%
Payout (12M): BBC $0.66; IBBQ $0.39
Last payment: BBC $0.66; IBBQ $0.23
Ex-dividend: BBC Dec 22, 2025; IBBQ Sep 21, 2026
Paid on: BBC Dec 29, 2025; IBBQ Sep 25, 2026
Frequency: BBC Annual; IBBQ Quarterly

Distribution history

Per share, 2017 to 2026, same scale for both

BBCAnnual · 4 paymentsAll BBC payments⁠

IBBQQuarterly · 21 paymentsAll IBBQ payments⁠

BBC vs IBBQ Risk

Fall from peak · 5 years

BBC
IBBQ

Risk facts

VolatilityStd dev, 3 years: BBC 35.7%IBBQ 16.8%, better
Return per unit of riskSharpe ratio, 3 years: BBC 0.90IBBQ 1.22, better
Worst fallMax drawdown, 5 years: BBC −70.1%IBBQ −34.8%, better
Market sensitivityBeta, 5 years: BBC 1.31IBBQ 0.61; Market = 1

BBC and IBBQ in the news

All news⁠

Deep Dive
Health care's 1.8% week was four large caps, not a biotech rally
Sep 19, 2026BBC

Popular comparisons

BBCDvsXBIA
Virtus Biotech Clinical Trials ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.65% · 0.35%
Category
IBBQAvsXBIA
Invesco Nasdaq Biotechnology ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.19% · 0.35%
Category
BBCDvsIBBA
Virtus Biotech Clinical Trials ETF · iShares Biotechnology ETF
Expense ratio
0.65% · 0.44%
Category
IBBQAvsIBBA
Invesco Nasdaq Biotechnology ETF · iShares Biotechnology ETF
Expense ratio
0.19% · 0.44%
Category
BBCDvsBBPA
Virtus Biotech Clinical Trials ETF · Virtus Biotech ETF
Expense ratio
0.65% · 0.34%
Category
IBBQAvsBBPA
Invesco Nasdaq Biotechnology ETF · Virtus Biotech ETF
Expense ratio
0.19% · 0.34%
Category

BBC vs IBBQ

In short

Stated mandate

Why people hold it

Worth knowing

How BBC and IBBQ differ

Level by level

Sector

Country, concentration and asset class

Country by domicile

Concentration

Asset class

Holdings

Only in BBC

Only in IBBQ

Weight gaps

Cost over time

Year by year

Distribution history

Fall from peak · 5 years

Risk facts

Health care's 1.8% week was four large caps, not a biotech rally

How BBC and IBBQ differ

Level by level

Sector

Country, concentration and asset class

Country by domicile

Concentration

Asset class

Holdings

Only in BBC

Only in IBBQ

Weight gaps